, Singapore
445 views
Photo from press release/

SingHealth Duke-NUS launches $6m platform to advance disease research

It aims to identify targets for lab-developed diagnostic tests.

SingHealth Duke-NUS Academic Medical Centre (AMC) has launched Spatial Profiling and Disease Exploration (SPADE), a cross-institutional research platform backed by a $6m grant from the SingHealth Joint Office of Academic Medicine.

The platform aims to identify targets for lab-developed diagnostic tests and to form partnerships between clinical researchers and industry to bring those findings to patients.

SPADE will pool clinical, pathology and computational expertise across the AMC to study how diseases develop and why patients respond differently to the same treatment.

Longer term, SPADE aims to enable multiple diagnostic tests on a single tissue sample, reducing repeat biopsies, and to identify several drug targets at once.

It also plans to build a spatial tissue atlas, a molecular map of human tissues, to train artificial intelligence models and simulate disease behaviour.

The platform is led by the National Cancer Centre Singapore and co-led by Singapore General Hospital and Duke-NUS Medical School.
 

Join Singapore Business Review community
Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.